NewsBenzingaArmata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Benzinga 2026.09.23 11:09 (GMT+0) Open on Benzinga Other news Bored Ape NFTs Enter Solana With 8 Rare Cards Anthropic announces public benefit fund, commits 5% of shares to public interest Broadcom, Verizon among 9 US companies opposing tokenized trading of their stocks on OKXICE Exclusive | Some Wall Street Leaders are Weighing Bailing on ‘Davos in the Desert’ After Attacks on Riyadh Why 1 Analyst Is Cooling Their Stance on Red-Hot DELL Stock Intel vs. AMD: The CPU Comeback Has Become a 2-Stock Fight, But 1 Is the Better Buy
Exclusive | Some Wall Street Leaders are Weighing Bailing on ‘Davos in the Desert’ After Attacks on Riyadh
